Science Explorer Interactive view Map
Company · Cambridge · United States

Dicerna Pharmaceuticals (United States)

dicerna.comROR OpenAlex
Research works
40
▼ 14% vs 2013–17
Citations
806
19.9 per fractional work
Top-10% rate
42.1%
record average 16.5%
Open access
37%
world 28%

Not ranked overall: Dicerna Pharmaceuticals (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at Dicerna Pharmaceuticals (United States)?

Ranked on the composite score, Shanthi Ganesh lead among researchers whose main affiliation is Dicerna Pharmaceuticals (United States).

  1. 1 Shanthi Ganesh United States · #1,206,411 worldwide 39 citations · 15 works
All ranked researchers at Dicerna Pharmaceuticals (United States)

Which keywords describe research at Dicerna Pharmaceuticals (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Cancer, Gene Therapy, RNA Interference, siRNA Delivery, Tumor Targeting, Metabolic Syndrome, Immunotherapy and Biogenesis.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Cancer7▲ 12×14 topics
  2. Gene Therapy6▲ 56×4 topics
  3. RNA Interference4▲ 77×1 topic
  4. siRNA Delivery4▲ 115×1 topic
  5. Tumor Targeting3▲ 54×3 topics
  6. Metabolic Syndrome3▲ 7.7×5 topics
  7. Nanoparticles3▲ 5.0×5 topics
  8. Immunotherapy3▲ 10.0×4 topics
  9. Biogenesis2▲ 54×3 topics
  10. Epigenetic Regulation2▲ 29×2 topics
  11. Management2▲ 7.7×4 topics
  12. Cancer Progression2▲ 25×2 topics
  13. Treatment2▲ 4.3×4 topics
  14. RNA methylation2▲ 62×1 topic
  15. m6A-seq2▲ 62×1 topic
  16. Regulation2▲ 7.7×3 topics
  17. Risk Factors2▲ 4.6×2 topics
  18. Prevalence2▲ 11×1 topic
  19. Urolithiasis2▲ 165×1 topic
  20. Translation2▲ 20×2 topics
  21. Tumor Regression2▲ 48×2 topics
  22. Biomarkers2▲ 6.5×3 topics
  23. Cancer Therapy2▲ 6.2×8 topics
  24. Drug Delivery2▲ 8.4×3 topics
  25. Transcriptional Regulation2▲ 16×3 topics
  26. Immunity2▲ 11×2 topics
  27. Long Noncoding RNAs2▲ 59×1 topic
  28. RNA Regulation2▲ 33×1 topic
  29. Tumor Microenvironment2▲ 10×3 topics
  30. Arginine Deprivation1▲ 78×1 topic
  31. Bacterial Therapy1▲ 78×1 topic
  32. Therapeutic Targets1▲ 15×4 topics
  33. Liver Transplantation1▲ 21×4 topics
  34. Cancer Immunotherapy1▲ 21×2 topics
  35. Cell Proliferation1▲ 32×2 topics
  36. Immune Checkpoint Blockade1▲ 52×1 topic
  37. PD-1 and PD-L11▲ 52×1 topic
  38. Inhibitors1▲ 37×2 topics
  39. Metastasis1▲ 7.8×2 topics
  40. DNA nanotechnology1▲ 25×1 topic

Which research topics does Dicerna Pharmaceuticals (United States) publish most on?

By volume in 2022–2025: Kidney Stones and Urolithiasis Treatments, Lipid metabolism and disorders, RNA Interference and Gene Delivery and Immunotherapy and Immune Responses.

Kidney Stones and Urolit…1Kidney Stones and Urolithiasis Treatments: 1 fractional worksLipid metabolism and disorders: 0 fractional worksRNA Interference and Gene Delivery: 0 fractional worksImmunotherapy and Immune Responses: 0 fractional worksMicroRNA in disease regulation: 0 fractional worksCancer-related molecular mechanisms research: 0 fractional worksImmune Cell Function and…0Immune Cell Function and Interaction: 0 fractional worksCancer, Lipids, and Metabolism: 0 fractional worksDNA Repair Mechanisms: 0 fractional worksLiver Diseases and Immun…0Liver Diseases and Immunity: 0 fractional works
Pulmonary and Respiratory MedicineCardiology and Cardiovascular MedicineMolecular BiologyImmunology2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Kidney Stones and Urolithiasis Treatments Pulmonary and Respiratory Medicine 1 works
  2. 2 Lipid metabolism and disorders Cardiology and Cardiovascular Medicine 0 works
  3. 3 RNA Interference and Gene Delivery Molecular Biology 0 works
  4. 4 Immunotherapy and Immune Responses Immunology 0 works
  5. 5 MicroRNA in disease regulation Cancer Research 0 works
  6. 6 Cancer-related molecular mechanisms research Cancer Research 0 works
  7. 7 Immune Cell Function and Interaction Immunology 0 works
  8. 8 Cancer, Lipids, and Metabolism Cancer Research 0 works
  9. 9 DNA Repair Mechanisms Molecular Biology 0 works
  10. 10 Liver Diseases and Immunity Hepatology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available37.0%not open63.0%

World: 28% of research is openly available.

with international co-authors22.8%domestic only77.2%

World: 19% is written across borders.

How has Dicerna Pharmaceuticals (United States)'s research output changed?

Output in 2018–2022 was 14% lower than in 2013–2017.

201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Cambridge

All research institutions in Cambridge

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.